skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Products

Show More

Show More

65 Total results for product and free and sample content found

Breast Cancer Clinical Landscape and Recent Trends Whitepaper

27 Nov 2020

White paper

Get a deeper understanding of breast cancer clinical trials initiated since 2014 and what the trends have meant for strategies in this area, with this free whitepaper from Citeline.

Topic Cancer Clinical Trials Research & Development

In Vivo

A Tale Of Two Pipelines

By Dennis Chang; Keith Flaherty; Uciane Scarlett 27 Nov 2020

A_Tale_Of_Two_Pipelines_1

Immuno-oncology has produced some exciting successes, but the field has become intensely crowded. Enormous resources are being poured into duplicative work and shaky hypotheses—overshadowing other pursuits in cancer research while producing limited results. It is time to re-evaluate how the sector should be pursuing innovation in cancer and how it can be smarter in its use of resources—financial investment, talent, bandwidth, patients and data.

Topic Cancer Research & Development

A Decade in Review: Oncology Trial Benchmarks and Sponsor Analysis

By Christine Blazynski, PhD 27 Nov 2020

A Decade in Review: Oncology Trial Benchmarks and Sponsor Analysis

The average cost of bringing a new drug to market continues to rise, with varying levels of investments across the highly competitive biopharmaceutical industry. To assess the potential effect of varying investments on trial activity and operations, this article reviews trial benchmarks within the active oncology therapeutic area. Industry-sponsored clinical trials across all oncology indications covered by Informa Pharma Intelligence’s Trialtrove were assessed, comparing metrics by company size based on pharma sales, and the identical benchmarks for breast cancer and rare cancers were also analyzed.

Topic Clinical Trials Cancer

In Vivo

Success in Oncology Infographic

24 Aug 2020

Success in Oncology Infographic

As events and developments in oncology rapidly shift and unfold, it’s more critical than ever to stay vigilant and agile to stay ahead.Understand these market disruptions and react to them with confidence with the data in Innovation in Oncology, the vital, free infographic from In Vivo.

Topic Cancer

Pink Sheet

US FDA Approval Of Lynparza For Pancreatic Cancer Opens Door For PFS Endpoint In Disease

By Michael Cipriano 08 Jan 2020

US_FDA_Approval_Of_Lynparza_1

AstraZeneca's PARP inhibitor Lynparza becomes first US FDA-approved drug for pancreatic cancer based on progression-free survival endpoint, providing regulatory precedent for other sponsors to use that development approach; all other pancreatic cancer drugs had been approved based on an overall survival benefit.

Topic Cancer Clinical Trials

Datamonitor Healthcare

Post-ESMO Podcast 2019

31 Oct 2019

Post-ESMO Podcast 2019

Listen to this podcast to keep up with the latest translational science and advancements in oncology to come out of the European Society of Medical Oncology (ESMO) Congress 2019. Datmonitor Healthcare’s post-event podcast delivers every important development.

Topic Cancer Research & Development

Biomedtracker, Datamonitor Healthcare

2019 Post-ESMO Conference Report Extract

31 Oct 2019

2019 Post-ESMO Conference Report Extract

Tap into insights and highlights from ESMO’s annual meeting of oncology clinicians, researchers, patient advocates, journalists, and members of the pharmaceutical industry.

Topic Cancer Drug Development Landscape Research & Development

Scrip

Imbruvica Replaces Chemo, Darzalex Boosts Standard Of Care In Front-Line CLL, Myeloma

By Mandy Jackson 02 Jul 2019

Imbruvica Replaces Chemo, Darzalex Boosts Standard Of Care In Front-Line CLL, Myeloma

Late-breaker presentations at ASH showed that replacing chemotherapy agents with Imbruvica in CLL, and adding Darzalex to Revlimid and dexamethasone in multiple myeloma, is more effective than current standards of care in certain front-line settings.

Topic Cancer Approvals

Scrip

Downward, Eastward or Inward? Blockbuster Film Puts Cancer Drug Prices In China Spotlight

By Brian Yang 02 Jul 2019

Downward, Eastward or Inward? Blockbuster Film Puts Cancer Drug Prices In China Spotlight

Bagging a $200m box office in its opening week in China, "Dying to Survive" is a sentimental movie about a Chinese businessman selling cancer drugs smuggled from India but unapproved in China that sees his life taking a drastic turn, from convicted felon to a Robin Hood-like hero as he helps those in need. The Chinese film authority’s clearance for the screening of the movie and the smash success signal three key messages about the future potential direction of oncology drugs in the country.

Topic Cancer

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: